Developer docs
API playgroundTry for free, no card

Search company profiles

Seqirus

Full company profile

uuid0008xqo

Namestring
Seqirus
Legal namestring
CSL Seqirus
Websiteurl
seqirus.com
Company typeenum
Private
Founded yearint
1916
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMaidenhead, United Kingdom
HQ citystring
Maidenhead
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
influenza vaccines, pandemic vaccines, biologics manufacturing, vaccine technology platform, public health biologics
Industry4 codes
PRIMARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAK
Vaccine Cold Chain, Storage & Distribution
SECONDARYHLAJAOAF
Immunization & Vaccine Access Partnerships (Global Vaccine Alliances)
SECONDARYBPADAIAB
Immunization & Vaccine Delivery Programs
Product category
Influenza Vaccines
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Influenza Vaccines
TypeOne Time License
Description

One of the world's largest influenza vaccine providers, developing and delivering seasonal and pandemic influenza vaccines to government and public health agencies globally.

csl.com
Cost components5 values
Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CSL Seqirus is one of the world's largest influenza vaccine providers, developing, manufacturing, and delivering seasonal and pandemic influenza vaccines to national governments and public health agencies globally. Operating as a wholly-owned subsidiary of CSL Limited, Seqirus focuses its portfolio on influenza vaccine products derived through CSL's vaccines technology R&D platform, with manufacturing and distribution supported by CSL Group's global infrastructure.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CSL Seqirus is a biotechnology company and one of the world's largest influenza vaccine providers, operating as part of the broader CSL group alongside CSL Behring and CSL Vifor. CSL Seqirus focuses on pandemic and seasonal influenza vaccines. The broader CSL portfolio includes: CSL Behring offering plasma-derived and recombinant biotherapies for rare and serious diseases (bleeding disorders, immune deficiencies, hereditary angioedema, Alpha 1 Antitrypsin Deficiency); CSL Seqirus providing influenza vaccines; and CSL Vifor addressing iron deficiency and nephrology. The company operates CSL Plasma, one of the world's largest vertically integrated plasma collection networks, supporting the manufacturing of biotherapeutics delivered to patients in more than 100 countries.

Product and service1 record
1CSL Seqirus Influenza Vaccines
CategoryVaccines
Description

Seasonal and pandemic influenza vaccines developed and manufactured by CSL Seqirus, supplied to national governments and public health agencies for routine immunization and pandemic preparedness programs.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Canada has awarded CSL Seqirus a contract for the development of an influenza pandemic vaccine. This contract is part of Canada's efforts to prepare for future influenza pandemics and enhance its public health response capabilities. The partnership represents a direct government engagement for pandemic preparedness.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeBroad incumbent
Description

Pfizer is a major pharmaceutical incumbent with a broad vaccines portfolio and significant influenza vaccine presence, competing against Seqirus for government pandemic and seasonal contracts.

TypeEmerging player
Description

An Indian vaccine manufacturer with growing influenza and pandemic preparedness capabilities, positioning itself as a cost-competitive alternative to Seqirus in emerging-market public health tenders.

3Sanofi Pasteur
TypeDirect peer
Description

Sanofi's vaccines division is one of the world's largest influenza vaccine manufacturers (e.g., Fluzone). Directly competes with Seqirus in seasonal and pandemic flu vaccines sold to governments and public health agencies globally.

4CSK (Kitasato Daiichi Sankyo Vaccines)
TypeRegional player
Description

A leading Japanese influenza vaccine manufacturer serving primarily the Japanese domestic market, offering a regional comparison point for Seqirus's pandemic and seasonal influenza business.

5Sinovac Biotech
TypeRegional player
Description

A major Chinese vaccine manufacturer with an influenza vaccine franchise, primarily competing in Asian markets but with growing global aspirations that could intersect with Seqirus's footprint.

TypeEmerging player
Description

Novavax applies recombinant nanoparticle technology to influenza vaccine development, positioning it as an emerging alternative approach that could compete with Seqirus in select markets.

7Hualan Biological Engineering
TypeRegional player
Description

One of China's largest influenza vaccine manufacturers, serving primarily the Chinese public health market but with growing export ambitions that could pressure Seqirus in price-sensitive geographies.

TypeDirect peer
Description

GSK's vaccines business markets major influenza vaccines (Fluarix, Flulaval) and competes directly with Seqirus across both seasonal and pandemic influenza procurement channels.

9AstraZeneca (FluMist)
TypeDirect peer
Description

AstraZeneca markets FluMist, a live attenuated influenza vaccine, positioning it as a direct competitor in the influenza vaccine market that Seqirus serves.

TypeEmerging player
Description

Moderna is developing mRNA-based influenza vaccine candidates that, if approved, would compete directly with Seqirus's traditional influenza vaccine portfolio, representing a potential technology disruption.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Seqirus

Influenza Vaccinesseqirus.com

Seqirus firmographics

Firmographics
Name
Seqirus
Legal name
CSL Seqirus
Website
https://seqirus.com
Company type
Private
Founded year
1916
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Seqirus industry classification

Industry
Product category
Influenza Vaccines
akta.pro industry
PRIMARYHLAAAEAJ
Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAK
Vaccine Cold Chain, Storage & Distribution
SECONDARYHLAJAOAF
Immunization & Vaccine Access Partnerships (Global Vaccine Alliances)
SECONDARYBPADAIAB
Immunization & Vaccine Delivery Programs

Keywords

  • Influenza vaccines
  • Pandemic vaccines
  • Biologics manufacturing
  • Vaccine technology platform
  • Public health biologics

Where Seqirus is headquartered

Location

Headquarters

HQ city
Maidenhead
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Seqirus business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure

Revenue model

  1. Influenza Vaccines: One of the world's largest influenza vaccine providers, developing and delivering seasonal and pandemic influenza vaccines to government and public health agencies globally.

Go-to-market motion1 record

Seqirus product offering

Product offering

Core offering

CSL Seqirus is one of the world's largest influenza vaccine providers, developing, manufacturing, and delivering seasonal and pandemic influenza vaccines to national governments and public health agencies globally. Operating as a wholly-owned subsidiary of CSL Limited, Seqirus focuses its portfolio on influenza vaccine products derived through CSL's vaccines technology R&D platform, with manufacturing and distribution supported by CSL Group's global infrastructure.

Product overview

CSL Seqirus is a biotechnology company and one of the world's largest influenza vaccine providers, operating as part of the broader CSL group alongside CSL Behring and CSL Vifor. CSL Seqirus focuses on pandemic and seasonal influenza vaccines. The broader CSL portfolio includes: CSL Behring offering plasma-derived and recombinant biotherapies for rare and serious diseases (bleeding disorders, immune deficiencies, hereditary angioedema, Alpha 1 Antitrypsin Deficiency); CSL Seqirus providing influenza vaccines; and CSL Vifor addressing iron deficiency and nephrology. The company operates CSL Plasma, one of the world's largest vertically integrated plasma collection networks, supporting the manufacturing of biotherapeutics delivered to patients in more than 100 countries.

Differentiator

Problem solved

Functional benefit

Products and services

  • CSL Seqirus Influenza Vaccines Seasonal and pandemic influenza vaccines developed and manufactured by CSL Seqirus, supplied to national governments and public health agencies for routine immunization and pandemic preparedness programs.

Companies that use Seqirus

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Seqirus technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Seqirus partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Government of CanadacoreStrategic or Co-development Partner · 17 March 2026Canada has awarded CSL Seqirus a contract for the development of an influenza pandemic vaccine. This contract is part of Canada's efforts to prepare for future influenza pandemics and enhance its public health response capabilities. The partnership represents a direct government engagement for pandemic preparedness.

Scale indicators2 records

Recent moves4 records

Seqirus competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Pfizer is a major pharmaceutical incumbent with a broad vaccines portfolio and significant influenza vaccine presence, competing against Seqirus for government pandemic and seasonal contracts.

Emerging players

  • Bharat Biotech: An Indian vaccine manufacturer with growing influenza and pandemic preparedness capabilities, positioning itself as a cost-competitive alternative to Seqirus in emerging-market public health tenders.
  • Novavax: Novavax applies recombinant nanoparticle technology to influenza vaccine development, positioning it as an emerging alternative approach that could compete with Seqirus in select markets.
  • Moderna: Moderna is developing mRNA-based influenza vaccine candidates that, if approved, would compete directly with Seqirus's traditional influenza vaccine portfolio, representing a potential technology disruption.

Direct peers

  • Sanofi Pasteur: Sanofi's vaccines division is one of the world's largest influenza vaccine manufacturers (e.g., Fluzone). Directly competes with Seqirus in seasonal and pandemic flu vaccines sold to governments and public health agencies globally.
  • GSK: GSK's vaccines business markets major influenza vaccines (Fluarix, Flulaval) and competes directly with Seqirus across both seasonal and pandemic influenza procurement channels.
  • AstraZeneca (FluMist): AstraZeneca markets FluMist, a live attenuated influenza vaccine, positioning it as a direct competitor in the influenza vaccine market that Seqirus serves.

Regional players

  • CSK (Kitasato Daiichi Sankyo Vaccines): A leading Japanese influenza vaccine manufacturer serving primarily the Japanese domestic market, offering a regional comparison point for Seqirus's pandemic and seasonal influenza business.
  • Sinovac Biotech: A major Chinese vaccine manufacturer with an influenza vaccine franchise, primarily competing in Asian markets but with growing global aspirations that could intersect with Seqirus's footprint.
  • Hualan Biological Engineering: One of China's largest influenza vaccine manufacturers, serving primarily the Chinese public health market but with growing export ambitions that could pressure Seqirus in price-sensitive geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Seqirus social profiles

Digital presence

Seqirus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Seqirus leadership team

Management profile

Number of profiles

Seqirus funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Seqirus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seqirus

What does Seqirus do?

CSL Seqirus is one of the world's largest influenza vaccine providers, developing, manufacturing, and delivering seasonal and pandemic influenza vaccines to national governments and public health agencies globally. Operating as a wholly-owned subsidiary of CSL Limited, Seqirus focuses its portfolio on influenza vaccine products derived through CSL's vaccines technology R&D platform, with manufacturing and distribution supported by CSL Group's global infrastructure.

Is Seqirus a public or private company?

Seqirus is a private company. It is classified as corporate owned and is currently operating.

When was Seqirus founded?

Seqirus was founded in 1916. It employs 1,001 to 5,000 people.

Where is Seqirus based?

Seqirus is headquartered in Maidenhead, United Kingdom, in the Europe region.

How does Seqirus make money?

One revenue line is on record: influenza Vaccines.

Who are Seqirus's main competitors?

Pfizer is listed as a broad incumbent. Emerging players are Bharat Biotech, Novavax and Moderna. Direct peers are Sanofi Pasteur, GSK and AstraZeneca (FluMist). Regional players are CSK (Kitasato Daiichi Sankyo Vaccines), Sinovac Biotech and Hualan Biological Engineering.

Does Seqirus have an API?

No public API is recorded for Seqirus.

What industry is Seqirus in?

Seqirus's product category is Influenza Vaccines. Its primary akta.pro industry code is HLAAAEAJ, Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable), with a secondary code of HLAIAEAK, Vaccine Cold Chain, Storage & Distribution.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales